KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Financing Activities (2016 - 2026)

Pacira BioSciences has reported Cash from Financing Activities over the past 17 years, most recently at -$59.4 million for Q1 2026.

  • For Q1 2026, Cash from Financing Activities fell 1883.9% year-over-year to -$59.4 million; the TTM value through Mar 2026 reached -$426.0 million, down 2578.94%, while the annual FY2025 figure was -$369.6 million, 2228.82% down from the prior year.
  • Cash from Financing Activities for Q1 2026 was -$59.4 million at Pacira BioSciences, down from -$51.7 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $25.0 million in Q2 2024 and troughed at -$257.5 million in Q3 2025.
  • A 5-year average of -$58.6 million and a median of -$27.8 million in 2023 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 5577.27% in 2024 and later plummeted 8950.12% in 2025.
  • Year by year, Cash from Financing Activities stood at -$58.5 million in 2022, then surged by 96.96% to -$1.8 million in 2023, then dropped by 9.89% to -$2.0 million in 2024, then plummeted by 2542.05% to -$51.7 million in 2025, then decreased by 15.0% to -$59.4 million in 2026.
  • Business Quant data shows Cash from Financing Activities for PCRX at -$59.4 million in Q1 2026, -$51.7 million in Q4 2025, and -$257.5 million in Q3 2025.